Alexey V Danilov
City of Hope Medical Center · Dartmouth-Hitchcock Norris Cotton Cancer Centre · Dartmouth-Hitchcock Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexey V Danilov as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07218510 · Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialCity of Hope Medical Center · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph1NCT06735664 · Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationCity of Hope Medical Center · recruiting · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome · principal investigator
- Ph2NCT06572618 · Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaCity of Hope Medical Center · recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT05672355 · A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center · completed · Chronic Lymphocytic Leukemia, COVID-19 Infection · principal investigator
- Ph2NCT04783415 · Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaCity of Hope Medical Center · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT03961672 · Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCity of Hope Medical Center · active not recruiting · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT03884998 · Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaCity of Hope Medical Center · active not recruiting · Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma · principal investigator
- Ph1NCT02117336 · Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Piramal Enterprises Limited · suspended · Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) · principal investigator
- Ph1NCT01832922 · BR in Patients With CLL With Comorbidities and/or Renal DysfunctionDartmouth-Hitchcock Medical Center · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- N/ANCT01466504 · Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human SkinDartmouth-Hitchcock Medical Center · terminated · Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma · principal investigator
- Early Ph1NCT01463852 · A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)Dartmouth-Hitchcock Medical Center · terminated · Chronic Lymphocytic Leukemia (CLL) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $1,915,725 awarded in 2026Same name and institution; not confirmed by an ID
- Overcoming ibrutinib resistance in mantle cell lymphomaR01CA244576 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2021 to 2025 · $450,309 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2018 to 2026
- Administration CoreP30CA023108 · NCI · DARTMOUTH COLLEGE · PI Robert W Gerlach · fiscal years 2018 to 2026Named on NCT01832922
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:54 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Br J Clin Pharmacol · 201794 citationsRCR 3.6
- Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.Clin Cancer Res · 202048 citationsRCR 1.8
- Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.Br J Haematol · 202126 citationsRCR 1.3
- Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.Leuk Lymphoma · 201725 citationsRCR 0.9
- Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.Leukemia · 202113 citationsRCR 0.6
- Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.Br J Clin Pharmacol · 202212 citationsRCR 0.9
- Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.Haematologica · 202512 citationsRCR 2.1
- A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.Invest New Drugs · 202110 citationsRCR 0.5
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.Blood Adv · 202510 citationsRCR 2.7
- A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Blood Adv · 20259 citationsRCR 2.3